Dr. Vandermolen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Old Newport Blvd
Newport Beach, CA 92663Phone+1 949-646-6441Fax+1 949-646-5719
Summary
- Dr. Louis Vandermolen is an oncologist in Newport Beach, CA and is affiliated with multiple hospitals in the area, including Hoag Memorial Hospital Presbyterian, Keck Hospital of USC, and USC Norris Comprehensive Cancer Center. He received his medical degree from Loyola University Chicago Stritch School of Medicine and has been in practice 37 years. He is experienced in squamous cell carcinoma of the esophagus, medullary carcinoma of the breast, inflammatory breast cancer, male breast cancer, and thymoma. He has more than 30 publications and over 450 citings.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
Baylor College of MedicineFellowship, Hematology, 1983 - 1984
Methodist Hospital (Houston)Chief Residency, Internal Medicine, 1983 - 1984- Baylor College of MedicineResidency, Internal Medicine, 1980 - 1983
Loyola University Chicago Stritch School of MedicineClass of 1980
Certifications & Licensure
CA State Medical License 1983 - 2025
AR State Medical License 1986 - 1991
MD State Medical License 1987 - 1991
TN State Medical License 1989 - 1990
TX State Medical License 1981 - 1988- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Publications & Presentations
PubMed
- 1 citationsDotatate PET/CT andAc-Dotatate Therapy for Somatostatin Receptor-expressing Metastatic Breast Cancer.Gary A Ulaner, Louis A VanderMolen, Gary Li, Denis Ferreira
Radiology. 2024-07-01 - 17 citationsShould high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma?Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, Khosrow Mahdavi, Stephanie E. McClure
Cancer Biotherapy & Radiopharmaceuticals. 2012-07-17 - 2 citationsA retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced ...Brian S. Kim, Robert O. Dillman, Peter Chen, Russell Hafer, Craig Cox
American Journal of Otolaryngology. 2012-01-01
Press Mentions
Almost 20% of Breast Cancer Survivors May Experience Excess Weight Gain, Study ReportsJune 6th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
